Arvinas (ARVN) Expected to Announce Earnings on Tuesday

Arvinas (NASDAQ:ARVN - Get Free Report) is expected to be announcing its earnings results before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of ($1.07) per share and revenue of $62.79 million for the quarter. Individual interested in registering for the company's earnings conference call can do so using this link.

Arvinas (NASDAQ:ARVN - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period last year, the firm posted ($2.53) EPS. On average, analysts expect Arvinas to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Arvinas Price Performance

Arvinas stock traded down $0.60 during trading hours on Friday, hitting $17.77. The company had a trading volume of 1,871,324 shares, compared to its average volume of 974,833. The firm has a market capitalization of $1.22 billion, a P/E ratio of -6.42 and a beta of 1.88. The firm's fifty day moving average is $18.49 and its 200-day moving average is $22.94. Arvinas has a fifty-two week low of $16.61 and a fifty-two week high of $51.51.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Stifel Nicolaus dropped their price objective on shares of Arvinas from $63.00 to $51.00 and set a "buy" rating on the stock in a research note on Wednesday, February 12th. HC Wainwright reiterated a "buy" rating and issued a $87.00 price objective on shares of Arvinas in a research note on Wednesday, December 11th. Stephens started coverage on shares of Arvinas in a research note on Monday, November 18th. They issued an "overweight" rating and a $55.00 price objective on the stock. Barclays decreased their target price on shares of Arvinas from $48.00 to $32.00 and set an "overweight" rating for the company in a research report on Monday, February 3rd. Finally, BTIG Research started coverage on shares of Arvinas in a research report on Tuesday, December 10th. They issued a "buy" rating and a $69.00 target price for the company. Thirteen equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $60.00.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.